{"id":36276,"date":"2020-12-23T12:00:00","date_gmt":"2020-12-23T12:00:00","guid":{"rendered":"http:\/\/touchoncology.com\/?post_type=media_gallery&#038;p=36276"},"modified":"2020-12-23T12:00:00","modified_gmt":"2020-12-23T12:00:00","slug":"steven-pipe-ash-2020-first-results-from-the-hope-b-gene-therapy-trial","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/haematology\/conference-hub\/steven-pipe-ash-2020-first-results-from-the-hope-b-gene-therapy-trial\/","title":{"rendered":"Steven Pipe, ASH 2020 \u2013 First Results from the HOPE-B Gene Therapy Trial"},"content":{"rendered":"<p>We had the pleasure to talk to <strong>Steven Pipe<\/strong> (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract &#8216;First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies&#8217; (ABSTRACT NUMBER: LBA-6) was presented at the Virtual 2020 ASH Congress, 2\u201310 December 2020.<\/p>\n<p><strong>Questions<\/strong><\/p>\n<ol>\n<li>What are the major challenges and opportunities of gene therapy for haemophilia B? (0:18)<\/li>\n<li>What is etranacogene dezaparvovec and how does it differ from other gene therapy candidates? (3:13)<\/li>\n<li>What were the aims and design of the HOPE-B study? (4:59)<\/li>\n<li>What have we learned from the first data from this study and what other endpoints will be assessed at 52 weeks? (6:48)<\/li>\n<\/ol>\n<p><strong>Disclosures:<\/strong> Steven Pipe has served as a consultant to Apcintex, Bayer, Biomarin, Catalyst Biosciences, CSL Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche\/Genentech, Sangamo Therapeutics, Sanofi, Takeda, Spark Therapeutics and uniQure.<\/p>\n<p><strong>Support:<\/strong> Interview and filming supported by Touch Medical Media Ltd.<\/p>\n<p><strong>Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract &#8216;First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe [&hellip;]<\/p>\n","protected":false},"featured_media":36340,"template":"","class_list":["post-36276","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-haematology","video_categories-ash-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/36276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":1,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/36276\/revisions"}],"predecessor-version":[{"id":36277,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/36276\/revisions\/36277"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/36340"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=36276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}